Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials
April 14 (Reuters) - Aditxt Inc ADTX.O:
ADITXT SUBSIDIARY ADIMUNE ANNOUNCES POSITIVE RESULTS FROM MAYO CLINIC PRE-CLINICAL STUDIES TO SUPPORT FDA AND EUROPEAN REGULATORY SUBMISSIONS FOR TYPE 1 DIABETES, PSORIASIS, AND STIFF PERSON SYNDROME HUMAN TRIALS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.